Embecta Aktie Logo
US29082K1051
A3DGNE
EMBC

Embecta Aktie

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 4,54 (-19,93%). A mediana é € 4,54 (-19,93%).

Comprar
  0
Manter
  2
Vender
  2

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Embecta exceeds Q3 expectations and raises full-year outlook

    Embecta reported adjusted EPS of $0.56 and revenue of $271.7 million for Q3 2026, significantly beating consensus estimates. The company raised its forecasts for adjusted operating margin to 23.5–24% and adjusted EPS to $1.80–1.90, but left its 2026 revenue guidance unchanged. Despite a year‑over‑year revenue decline, Embecta benefited from cost cuts, the contribution from the acquisition of Owen Mumford and a sequential improvement in results; however, the U.S. business remains under pressure. » Mais em de.investing.com


  • Embecta resets U.S. outlook after retailer share loss and pushes GLP-1, Owen Mumford diversification

    Embecta cut its U.S. guidance after a challenging quarter marked by loss of shelf position at a major retailer—attributed mainly to price pressure—softer insulin pen prescriptions and inventory adjustments. CEO Devdatt Kurdikar said the company is assessing whether the weakness is temporary or structural amid rising GLP-1 affordability and insurance changes. Embecta is accelerating diversification via lower‑priced pen needles and syringes, a GLP‑1 B2B channel and the pending Owen Mumford acquisition while targeting about $100 million in free cash flow and prioritizing debt reduction and buybacks. » Mais em finance.yahoo.com


  • S&P downgrades Embecta to B after sales decline in pen needles

    S&P Global Ratings cut Embecta’s rating from B+ to B with a stable outlook after second fiscal quarter sales fell 14%. Reasons cited include roughly 20% currency‑adjusted revenue weakness in insulin pen needles, market share losses to a lower‑priced competitor, and weaker US market demand (lower insulin usage, a shift to cheaper channels, increased use of automated systems and GLP‑1 drugs). S&P expects about a 6% sales decline in 2026, an adjusted margin down roughly 800 basis points to 29%, and leverage of 4.5–5x; the acquisition of Owen Mumford is expected to be financed via the revolving credit facility and the dividend will be cut to reduce debt. » Mais em de.investing.com


  • Embecta misses Q2 2026 forecasts significantly, stock falls 44% premarket

    Embecta reported Q2 2026 EPS of $0.27 versus $0.42 expected and revenue of $221.8 million versus $235.66 million expected. Revenue fell 14.4% year-on-year, driven by a 29.4% decline in the US business, prompting the company to lower its full-year guidance. The stock plunged in premarket trading from $9.25 to $5.15. Management announced a review of the cost and organizational structure, brand and product initiatives, and the integration of Owen Mumford as a strategic move. » Mais em de.investing.com


  • Embecta to acquire Owen Mumford for up to £150 million

    Embecta has signed a definitive agreement to acquire British medical‑technology manufacturer Owen Mumford. On closing Embecta will pay £100 million in cash plus up to £50 million in contingent payments, depending on net sales of the Aidaptus autoinjector platform in the three years after closing. Owen Mumford recorded net sales of £69.4 million in 2025; the transaction is expected to close in the third quarter of fiscal 2026, subject to regulatory approvals. Embecta expects growth and long‑term accretion from 2027 but foresees a dilution of adjusted net income in 2027; financing will be partly provided through its revolving credit facility. » Mais em de.investing.com

Em 2026, Embecta Aktie já distribuiu € 0,15 em dividendos. A última distribuição ocorreu em setembro.

Dados financeiros da empresa

No último trimestre, Embecta Aktie registou receitas de € 238,07 mi e um ganho líquido de € 18,49 mi
(EUR) junho de 2026
YoY
Receitas 238,07 mi 5,04%
Ganho bruto 134,32 mi 18,81%
Ganho líquido 18,49 mi 52,11%
EBITDA 56,69 mi 39,58%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 332,62 mi
Número de ações
56,66 mi
Máximo/mínimo de 52 semanas
€ 13,46 - € 2,52
Rentabilidade de dividendos
4,87%
Dividendos TTM
€ 0,28
Beta
0,81
PER (PE Ratio)
4,34
PEG (PEG Ratio)
0,88
P/VC (PB Ratio)
-0,62
P/V (PS Ratio)
0,36

Perfil da empresa

A Embecta Corp., uma empresa de dispositivos médicos, dedica-se à oferta de diversas soluções para melhorar a saúde e o bem-estar das pessoas que vivem com diabetes. Os seus produtos incluem agulhas para canetas, seringas e dispositivos de segurança, bem como aplicações digitais que auxiliam as pessoas na gestão da sua diabetes. A empresa vende os seus produtos principalmente a grossistas e distribuidores nos Estados Unidos e a nível internacional. A Embecta Corp. foi fundada em 1924 e tem sede em Parsippany, Nova Jérsia. A Embecta Corp. (NasdaqGS:EMBC) opera de forma independente da Becton, Dickinson and Company desde 1 de abril de 2022.

Nome
Embecta Aktie
CEO
Devdatt Kurdikar
Sede Parsippany, nj
EUA
Site
Setor
Bens de consumo não essenciais
Indústria
Bens de consumo duradouros
Entrada em bolsa
22/03/2022
Colaboradores 1.850

Símbolos de ticker

Bolsa Símbolo
NASDAQ
EMBC
Frankfurt
JX7.F
Düsseldorf
JX7.DU
München
JX7.MU
🍪

Parqet  utiliza cookies. Saber mais